Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs ACHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 4 – 2 ACHC Matrix Metrics: CON 8 – 2 ACHC

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Acadia Healthcare Company, Inc. (ACHC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ACHC carries 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs ACHC
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
ACHC NASDAQ
Acadia Healthcare Company, Inc.
Services-Specialty Outpatient Facilities, Nec
$34.60
+0.38% 1D
Market Cap $3.2B
TTM Revenue $3.41B
Forward P/E 17.0x
Beta / 30D Vol 0.68β · 61% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 59.0 Mom 36.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.1% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $34.42 · SMA50: $31.28

6-Pillar Scorecard Institutional Category Breakdown (CON 4 – 2 ACHC)

Columns: Metric · CON · ACHC
1. Valuation Multiples ACHC
Forward P/E 22.0x 17.0x
Trailing P/E 24.5x 16.9x
PEG Ratio N/M 1.37x
EV / Revenue 3.1x 1.6x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% +5.1%
Earnings Growth (YoY) +36.4% -5.1%
TTM Revenue (USD) $2.34B $3.41B
Market Cap $5.2B $3.2B
3. Profitability & Quality CON
Gross Margin 29.9% 41.0%
Operating Margin 17.2% 9.8%
Net Profit Margin 9.3% -33.1%
Return on Equity (ROE) 47.2% -40.5%
4. Balance Sheet & Cash Flow CON
Cash Generation (TTM) $257M -$24M
Cash Flow Margin 11.0% -0.7%
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $2.34B Net Debt (1.24x D/E)
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 269.9% (95th %ile) 49.8% (31st %ile)
Put/Call OI Skew 0.79x (Call-Skewed) 0.39x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ACHC
OpEx & R&D Intensity 12.7% of Rev ($297M) 31.2% of Rev ($1.06B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (8) vs ACHC (2)
Institutional Metric CON ACHC Criterion Row Edge
Market Capitalization
Scale
$5.2B $3.2B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x 16.9x Lower Multiple ACHC
Forward P/E Ratio
Valuation
22.0x 17.0x Lower Multiple ACHC
Revenue Growth (YoY)
Growth
+8.6% +5.1% Higher Growth CON
Operating Margin (TTM)
Profitability
17.2% 9.8% Higher Margin CON
Net Profit Margin
Profitability
9.3% -33.1% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% -40.5% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 82% ($11–$40) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol 0.68β · 61% Vol Lower Realized Risk CON
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 33.1 / 100 (SELL) Higher Composite CON
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $3.41B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 41.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.37x PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) -$24M ($2.34B Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACHC +3.85 pp
CON: +4.68% · ACHC: +8.53%
3M Horizon ACHC +0.89 pp
CON: +19.58% · ACHC: +20.47%
6M Horizon CON +15.97 pp
CON: +65.24% · ACHC: +49.27%
1Y Horizon ACHC +23.7 pp
CON: +117.58% · ACHC: +141.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CON Revenue ACHC Revenue CON Op. Margin ACHC Op. Margin Margin Leader
FY2018 N/A $1.90B N/A 31.2% ACHC
FY2019 N/A $2.01B N/A 29.2% ACHC
FY2020 N/A $2.09B N/A -32.2% ACHC
FY2021 N/A $2.31B N/A 8.2% ACHC
FY2022 $1.72B $2.61B 15.0% 10.5% CON
FY2023 $1.84B $2.93B 15.6% -0.7% CON
FY2024 $1.90B $3.15B 16.0% 8.1% CON
FY2025 $2.16B $3.31B 15.4% -33.3% CON

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHC CONSOLIDATION
87d in phase · OBV NEUTRAL
Current IV 49.8%
IV Percentile 31st %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ACHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $38.10 · IV 47.7%

ACHC Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,810)

Compare $3,810 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 47.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $35 / $30 Bull Put Spread

Sell 1x $35P · Buy 1x $30P · 59d

Net Entry $112 Credit
Max Credit / Yield +$112 (+28.9% RoM)
Max Risk / Buffer -11.1% Cushion ($388 Mgn)
5d Edge & Liquidity 71% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $40 / $35 Bear Put Spread

Buy 1x $40P · Sell 1x $35P · 31d

Net Entry $220 Debit
T+5d @ -5% Drop +$73 (+33%)
Max Risk / Buffer $220 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
ACHC Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.2B market capitalization and 9.8% operating margin.
OpEx & R&D Reinvestment 31.2% of Rev ($1.06B)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs ACHC Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Acadia Healthcare Company, Inc. (ACHC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ACHC carries 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin). Technically, CON sits in a Markup phase (RSI 55.6, BREAKOUT options structure) and ACHC sits in a Markup phase (RSI 51.8, CONSOLIDATION options structure).

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with ACHC at +5.1% YoY revenue growth and -5.1% YoY earnings growth on $3.41B TTM revenue (41.0% gross margin, 9.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CON cumulative revenue shifted +25.6% while ACHC shifted +74.2%. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 31.2% of Rev ($1.06B) (0 disclosures) for ACHC.

ACHC screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas ACHC trades at 17.0x Forward P/E, 16.9x Trailing P/E, 1.37x PEG, and 1.6x EV/Revenue (-0.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus ACHC (-40.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, ACHC carries 49.8% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.68β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.